Evidence map›Paper›PMID 20178980›Full record

ArticleThe Journal of biological chemistry2010

cAMP/CREB-mediated transcriptional regulation of ectonucleoside triphosphate diphosphohydrolase 1 (CD39) expression.

Hui Liao, Matthew C Hyman, Amy E Baek, Keigo Fukase, David J Pinsky

Abstract read
In one paragraph

Article in The Journal of biological chemistry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed.

  1. Trial
  2. Trial
  3. CD8MedComm · 2026
    Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. CD39 Regulation and Functions in T Cells.International journal of molecular sciences · 2021
    Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hui LiaoDepartment of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA.
Matthew C Hyman
Amy E Baek
Keigo Fukase
David J Pinsky

Funding

Thrombotic/Fibrinolytic Balance in Cardiac Transplant VasculopathyP01HL089407 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LAWRENCE, DANIEL A · 2008 to 2012
$7.9M
VASCULAR BIOLOGY OF LUNG PRESERVATIONR01HL055397 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PINSKY, DAVID J. · 1996 to 2008
$2.9M
Ectonucleotidases in Atherothrombosis and StrokeR01HL086676 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PINSKY, DAVID J. · 2007 to 2011
$1.8M
Eicosanoid Balance in Lung Transplant Injury and RepairR01HL085149 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PINSKY, DAVID J. · 2006 to 2009
$1.7M
NHLBI NIH HHS P01 HL089407NHLBI NIH HHS P01HL089407NHLBI NIH HHS R01 HL055397NHLBI NIH HHS R01HL055397NHLBI NIH HHS R01 HL085149NHLBI NIH HHS R01HL085149NHLBI NIH HHS R01 HL086676NHLBI NIH HHS R01HL086676
6 · The paper itself

Abstract

CD39 is a transmembrane enzyme that inhibits platelet reactivity and inflammation by phosphohydrolyzing ATP and ADP to AMP. Cyclic AMP (cAMP), an essential second messenger, is particularly important in regulating genes controlling vascular homeostasis. These experiments test the hypothesis that cAMP might positively regulate the expression of CD39 and thereby modulate important vascular homeostatic properties. Cd39 mRNA was induced by 13.8- fold in RAW cells treated with a membrane-permeant cAMP analogue (8-bromo-cyclic AMP; 8-Br-cAMP), stimulation of adenylate cyclase, or prostanoids known to drive cAMP response. Fluorescence-activated cell sorting, immunofluorescence, and TLC assays demonstrated that both CD39 protein expression and enzymatic activity were increased in cells treated with 8-Br-cAMP but not in cells transfected with short hairpin RNA against CD39. This analogue drove a significant increase in transcriptional activity at the Cd39 promoter although not when the promoter's cAMP-response element sites were mutated. Pretreatment with cAMP-dependent protein kinase (PKA), phosphoinositide 3-kinase (PI3K), or ERK inhibitors nearly obliterated the cAMP-driven increase in Cd39 mRNA, protein expression, and promoter activity. 8-Br-cAMP greatly increased the phosphorylation of CREB1 (Ser(133)) and ATF2 (Thr(71)) in a PKA-, PI3K-, and ERK-dependent fashion. Chromatin immunoprecipitation assays demonstrated that binding of phosphorylated CREB1 and ATF2 to cAMP-response element-like sites was significantly increased with 8-Br-cAMP treatment and that binding was reduced with PKA, PI3K, and ERK inhibition, whereas transfection of Creb1 and Atf2 overexpression constructs enhanced cAMP-driven Cd39 mRNA expression. Transfection of RAW cells with mutated Creb1 (S133A) reduced cAMP-driven Cd39 mRNA expression. Furthermore, the cAMP-mediated induction of Cd39 mRNA, protein, and phosphohydrolytic activity was replicated in primary peritoneal macrophages. These data identify cAMP as a crucial regulator of macrophage CD39 expression and demonstrate that cAMP acts through the PKA/CREB, PKA/PI3K/ATF2, and PKA/ERK/ATF2 pathways to control a key vascular homeostatic mediator.

Indexed as

Gene Expression RegulationActivating Transcription Factor 2AnimalsAntigens, CDApyraseBlotting, WesternCells, CulturedChromatin ImmunoprecipitationCyclic AMPCyclic AMP-Dependent Protein KinasesCyclic AMP Response Element-Binding ProteinFlow CytometryFluorescent Antibody TechniqueMacrophages, PeritonealMaleMiceActivating Transcription Factor 2Antigens, CDApyraseAtf2 protein, mouseCD39 antigenCreb1 protein, mouseCyclic AMPCyclic AMP-Dependent Protein KinasesCyclic AMP Response Element-Binding ProteinRNA, Messenger

Identifiers

PMID20178980
PMCPMC2863166

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.